FDA clears Evolva’s IND for EV-077 in influenza
Neil Goldsmith, CEO and Managing Director of Evolva commented: “This regulatory clearance by the FDA is an important milestone in the development of EV-077. In preclinical testing, EV-077 has shown potential as prophylaxis and treatment of various viral infections. We believe the compound could have significant potential against influenza and in bio-defence.”
Evolva has entered into discussions with potential partners regarding the further development and marketing of the compound. Evolva owns the rights to all intellectual property surrounding EV-077.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.